Compare HOG & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HOG | DYN |
|---|---|---|
| Founded | 1903 | 1984 |
| Country | United States | United States |
| Employees | 6400 | N/A |
| Industry | Motor Vehicles | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.8B |
| IPO Year | 1994 | 2020 |
| Metric | HOG | DYN |
|---|---|---|
| Price | $29.32 | $16.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 17 |
| Target Price | $28.10 | ★ $36.00 |
| AVG Volume (30 Days) | 1.9M | ★ 2.9M |
| Earning Date | 10-29-2026 | 11-09-2026 |
| Dividend Yield | ★ 2.55% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.97 | N/A |
| Revenue | ★ $4,473,175,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.80 | N/A |
| P/E Ratio | $30.38 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.09 | $14.00 |
| 52 Week High | $29.63 | $27.31 |
| Indicator | HOG | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 64.61 | 52.98 |
| Support Level | $26.35 | $16.65 |
| Resistance Level | N/A | $17.31 |
| Average True Range (ATR) | 0.88 | 0.88 |
| MACD | 0.27 | 0.40 |
| Stochastic Oscillator | 84.70 | 91.82 |
Harley-Davidson is a leading global manufacturer of heavyweight motorcycles across the custom, cruising, and touring categories, as well as related merchandise, parts, and accessories. In recent years, the firm has expanded into the adventure touring market with its Pan America model, into electric with the LiveWire brand, and is returning to smaller-displacement bikes with the Sprint. Its captive finance arm, Harley-Davidson Financial Services, provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley captured around 34% of the heavyweight domestic market in 2025.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.